CLDN4 and ovarian carcinoma: CLDN4 knockdown increased cellular accumulation and sensitivity to cisplatin, pointing towards the potential involvement of CLDN4 in platinum resistance in ovarian cancer [125], in line with the enhanced sensitivity toward carboplatin and paclitaxel upon CLDN1 knockdown in ovarian cancer cells [126].